Article Details
Retrieved on: 2025-03-20 14:22:06
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
As previously reported, Wedbush initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $35 price target The firm notes its ...
Article found on: www.tipranks.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here